Symbols

AMPH

Amphastar·NASDAQ

--(--)

AMPH fundamentals

AMPH Q4 2025 Earnings

Amphastar (AMPH) released its earnings on Feb 26, 2026: revenue was 183.10M (YoY -1.83%), missed estimates; EPS was 0.73 (YoY -20.65%), missed estimates.

Revenue / YoY

183.10M

-1.83%

EPS / YoY

0.73

-20.65%

Report date

Feb 26, 2026

AMPH Earnings Call Summary for Q4,2025

Topline Growth: 2025 revenue $719.9M, driven by BAQSIMI (+12%) and new product launches. 2026 expects mid-high single-digit growth from ipratropium bromide launch and BAQSIMI US expansion.
Margin Challenges: 2026 gross margin pressure from legacy product pricing, offset by BAQSIMI US growth and intl. exit. API sales (~$30M) to weigh on margins.
Pipeline Momentum: 2026 launches for insulin aspart and GLP-1, with $60B+ addressable market in high-value therapeutics.
Strategic Priorities: US manufacturing expansion, disciplined cash deployment (buybacks vs. BD), and focus on high-margin proprietary assets.

Earnings

EPS

Revenue

Revenue & Expenses

AMPH has released its 2025 Q4 earnings report, with revenue of 183.10M, reflecting a YoY change of -1.83%, and net profit of 24.43M, showing a YoY change of -35.65%. The Sankey diagram below clearly presents AMPH's revenue sources and cost distribution.

Key Indicators

Amphastar (AMPH) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Amphastar (AMPH)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Amphastar (AMPH)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Amphastar (AMPH)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown